|
|
Article: Positive Clinical Data in Treating Female Sexual Arousal Disorder From VIVUS To Be Featured During ISSWSH.
- Article from:
- PR Newswire
- Article date:
- October 28, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
48 Percent Increase in Successful and Satisfactory Events in Women Who Completed Study With ALISTA
VIVUS Inc. today announced that the Company and its investigators will present positive results of a Phase 2 clinical study evaluating the safety and efficacy of ALISTA(TM) (topical alprostadil) for the treatment of Female Sexual Arousal Disorder (FSAD) in premenopausal women at the Annual Meeting of the International Society for the Study of Women's Sexual Health (ISSWSH). Stephanie Kuffel, Ph.D., acting instructor, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, will present these data during an oral podium ...